VBContract PerformanceClaims through 2026-09-30 · CY2026
Portfolio
MA Full Risk

Humana MA Global Cap

Quality within 5 pts of gate

Watch
Attributed lives
5,280
MLR
88.5%
$1098 spend vs $1240 revenue PMPM
Quality score
84
Gate 80
Projected settlement
$9.0M
Downside exposure $78.6M

Contract terms

Payer
Humana
Arrangement
Global capitation (% of premium)
Risk
Full Risk
Period
CY2026
Cap revenue
$1240 PMPM
Surplus share
100%
Quality gate
80

Data completeness

87%

Claims through 2026-09-30. Recent months completed with IBNR estimates.

PMPM spend vs cap revenue

Dashed = IBNR-estimated months

Quality measures

Marker = target
Controlling High BP
70% / 70%
Met
Diabetes HbA1c <9
76% / 75%
Met
Breast Cancer Screening
75% / 74%
Met
Colorectal Screening
68% / 68%
Met
Med Adherence – Statins
90% / 88%
Met

Utilization

Admits / 1000
210
ED / 1000
540
Readmit %
13.9
SNF days / 1000
870

Risk adjustment

1.31

▲ 0.05 vs prior year (1.26)

RAF drives benchmark / premium — falling RAF shrinks revenue.